Floatz logo

Azacitidine

MDS/AML

M.D. Anderson Cancer CenterSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the MDS/AML cohort.

Asset / SponsorPhaseRating
Thiotepa
University Hospital Tuebingen
Phase 2CCC
Fludarabine
University Hospital Tuebingen
Phase 2CCC
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
University Hospital Tuebingen
Phase 2CCC
Evomela
University Hospital Tuebingen
Phase 2CCC
Hydroxyurea
University Hospital Tuebingen
Phase 2CCC
ROPEGINTERFERON ALFA-2B
M.D. Anderson Cancer Center
Phase 1/2CC

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →
acute erythroid leukemiaDormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →